Annovis Bio Reports Significant Progress in Phase 3 Alzheimer's Trial with Promising Biomarker Data

Annovis Bio Inc. (NYSE: ANVS) has reported substantial progress in its late-stage clinical development program for neurodegenerative diseases, with the company's pivotal Phase 3 Alzheimer's study reaching full operational capacity across all 84 clinical trial sites in the United States. The clinical-stage pharmaceutical company announced these developments alongside promising biomarker data from its Phase 2/3 Alzheimer's trial that demonstrates significant reductions in both inflammation and neurodegeneration markers.

The biomarker findings provide compelling evidence supporting buntanetap's potential as a disease-modifying therapy for Alzheimer's disease. These results come at a critical time when the global healthcare community continues to seek effective treatments for neurodegenerative conditions affecting millions of patients worldwide. The company's progress represents an important step forward in addressing one of the most challenging areas of neurological medicine.

Beyond clinical advancements, Annovis Bio has strengthened its intellectual property position by transferring all patents related to the new crystal form of buntanetap, with protection extending through 2046. This strategic move secures long-term exclusivity for the company's lead therapeutic candidate. Additional corporate developments include the publication of supportive pharmacokinetic data and the appointment of experienced finance executive Mark Guerin as Chief Financial Officer, further strengthening the company's leadership team.

Maria Maccecchini, Ph.D., president and CEO of Annovis Bio, emphasized the significance of these achievements, stating that every element is now aligned as the company moves toward data readouts, which represent the final step before submitting a New Drug Application to regulatory authorities. The company's comprehensive approach addresses multiple aspects of drug development, from clinical execution to intellectual property protection and corporate governance.

For investors and stakeholders seeking additional information, the company maintains resources at https://www.annovisbio.com and provides updates through its corporate newsroom at https://ibn.fm/ANVS. The broader investment community can access financial communications services through platforms like https://www.InvestorWire.com, which specializes in wire-grade press release distribution and corporate communications solutions for public companies.

The progress reported by Annovis Bio holds significant implications for the Alzheimer's treatment landscape, potentially offering new hope for patients and caregivers affected by this devastating condition. As the Phase 3 trial advances toward completion, the medical community awaits further data that could validate buntanetap's mechanism of action and therapeutic benefits in addressing the underlying pathology of Alzheimer's disease.